Brief: Oncternal Therapeutics Presents Updated Interim Data For Zilovertamab In Combination With Ibrutinib At ASH 2021
13/12/2021 13:18
Dec 13 (Reuters) - Oncternal Therapeutics Inc ONCT.O :
* ONCTERNAL THERAPEUTICS PRESENTS UPDATED INTERIM DATA FOR
ZILOVERTAMAB IN COMBINATION WITH IBRUTINIB AT ASH 2021
* ONCTERNAL THERAPEUTICS INC - TO PROVIDE UPDATE ON CO'S
DIALOGUE
WITH FDA ON PHASE 3 STUDY DESIGN LATER THIS MONTH FOR
ZILOVERTAMAB WITH IBRUTINIB
Source text for Eikon: ID:nGNX2nfB3X
Further company coverage: ONCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncternal Therapeutics
See all newsOncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;